Cargando…

Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus

OBJECTIVE: To describe the rationale and design of the SIB trial, an interventional clinical trial testing the hypothesis that subcutaneous (s.c.) once-weekly semaglutide can improve intestinal permeability and reduce systemic inflammation in participants with type 2 diabetes (T2D) and obesity. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rella, Steven, Onyiah, Joseph, Baker, Chelsea, Singh, Vatsala, Her, Andrew, Rasouli, Neda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617296/ https://www.ncbi.nlm.nih.gov/pubmed/37916028 http://dx.doi.org/10.1177/20420188231207348

Ejemplares similares

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study
por: Miyake, Teruki, et al.
Publicado: (2022)

Should metformin remain the first-line therapy for treatment of type 2 diabetes?
por: Baker, Chelsea, et al.
Publicado: (2021)

Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale
por: Kubota, Yoshiaki, et al.
Publicado: (2018)

A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol
por: Li, Chen, et al.
Publicado: (2019)

Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial
por: Chang, Anne B, et al.
Publicado: (2012)

Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
por: Jensterle, Mojca, et al.
Publicado: (2021)

Sib1, Sib2, and Sib3 proteins are required for ferrichrome-mediated cross-feeding interaction between Schizosaccharomyces pombe and Saccharomyces cerevisiae
por: Brault, Ariane, et al.
Publicado: (2022)

Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol
por: Chang, Anne B, et al.
Publicado: (2011)

Group intervention for siblings and parents of children with chronic disorders (SIBS-RCT): study protocol for a randomized controlled trial
por: Fjermestad, Krister W., et al.
Publicado: (2020)

Rationale, design, and methodology for the optimizing outcomes in women with gestational diabetes mellitus and their infants study
por: Berry, Diane C, et al.
Publicado: (2013)

Mysterious SiB(3): Identifying the Relation between α- and β-SiB(3)
por: Eklöf, Daniel, et al.
Publicado: (2019)

Sib-pair subgroup familial type 1 diabetes mellitus in children in the state of Qatar
por: Afyouni, Houda, et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial
por: Son, Cheol, et al.
Publicado: (2019)

First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
por: Rajput, Rajesh, et al.
Publicado: (2022)

Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers
por: Gunning, Karen
Publicado: (2020)

Barriers, facilitators and preferences for the physical activity of school children. Rationale and methods of a mixed study
por: Martínez-Andrés, María, et al.
Publicado: (2012)

Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial
por: Maraone, Annalisa, et al.
Publicado: (2023)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
por: Zinman, Bernard, et al.
Publicado: (2014)

Barriers to successful implementation of care in home haemodialysis (BASIC-HHD):1. Study design, methods and rationale
por: Jayanti, Anuradha, et al.
Publicado: (2013)

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2017)

Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study
por: Van Tassell, Benjamin, et al.
Publicado: (2022)

Genomic prediction in hybrid breeding: II. Reciprocal recurrent genomic selection with full-sib and half-sib families
por: Melchinger, Albrecht E., et al.
Publicado: (2023)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)
por: Hansen, Baiba Hedegaard, et al.
Publicado: (2009)

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2017)

GCORE-sib: An efficient gene-gene interaction tool for genome-wide association studies based on discordant sib pairs
por: Sung, Pei-Yuan, et al.
Publicado: (2016)

Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)
por: Nomoto, Hiroshi, et al.
Publicado: (2021)

Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and design
por: Cho, Alex H, et al.
Publicado: (2012)

Prophylactic antibiotic for prevention of posttraumatic meningitis after traumatic pneumocephalus: design and rationale of a placebo-controlled randomized multicenter trial [ISRCTN71132784]
por: Eftekhar, Behzad, et al.
Publicado: (2006)

Effects of Melatonin on Glycemic Variability in Type 2 Diabetes Mellitus: Protocol for a Crossover, Double-Blind, Placebo-Controlled Trial
por: Martorina, Wagner, et al.
Publicado: (2023)

Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
por: Gaughran, Fiona, et al.
Publicado: (2020)

The sex ratios of offspring and sibs of patients with cancer.
por: James, W. H.
Publicado: (1996)

ExPASy: SIB bioinformatics resource portal
por: Artimo, Panu, et al.
Publicado: (2012)

Conservative versus surgical treatment of foot drop in peroneal nerve entrapment: rationale and design of a prospective, multi-centre, randomized parallel-group controlled trial
por: Oosterbos, Christophe, et al.
Publicado: (2022)

Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study
por: Myat, Aung, et al.
Publicado: (2015)

The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial
por: Sha, Zhongwei, et al.
Publicado: (2020)

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
por: Bain, Stephen C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dr98k3l2h3jo6edriao0apjk9e